Breaking News

Samsung Biologics Expands Capacity with Fifth Plant

Plant 5 will have 180,000 liters of manufacturing capacity, expanding the company's total site capacity to 784,000 liters upon completion.

Samsung Biologics, a contract development and manufacturing organization (CDMO), will begin construction of a fifth plant as part of its strategic expansion in response to increased market demand. The company plans to begin construction in the first half of 2023 and commence operations in 2025. As part of Samsung Biologics’ second Bio Campus, Plant 5 will have manufacturing capacity of 180,000 liters, expanding the company’s total site capacity to 784,000 liters upon its completio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters